{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T08:15:11Z","timestamp":1771229711262,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T00:00:00Z","timestamp":1591833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T00:00:00Z","timestamp":1591833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Hepatopancreaticobiliary malignancies with peritoneal carcinomatosis exhibit poor survival with current therapies: hepatocellular carcinoma 11\u2009months with sorafenib, and pancreaticobiliary 9\u201314\u2009months with systemic chemotherapy. However, limited data exist on the utility of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in these patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively reviewed our institutional hepatopancreaticobiliary malignancies with peritoneal carcinomatosis which underwent cytoreductive surgery and hyperthermic intraperitoneal chemotherapy from 2007 to 2017 and analyzed perioperative and oncologic outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Seventeen patients were included: 9 hepatocellular carcinoma, 8 pancreaticobiliary (4 cholangiocarcinoma, 3 gallbladder, 1 pancreatic). Peritoneal cancer index, number of organs resected, completeness of cytoreduction, and 30-day morbidity were equivalent. Hepatocellular carcinoma received significantly less neoadjuvant therapy (11%,<jats:italic>p<\/jats:italic>= 0.008), though adjuvant therapy rates were similar. At a median follow-up of 15\u2009months, progression-free survival was similar amongst all cohorts. However, overall survival was longer in hepatocellular carcinoma (42\u2009months vs. cholangiocarcinoma 19\u2009months, gallbladder 8\u2009months, pancreatic 15\u2009months,<jats:italic>p<\/jats:italic>= 0.206) with 59% 3-year overall survival (vs. 0% cholangiocarcinoma, 0% gallbladder, 0% pancreatic).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy may offer a survival benefit in select hepatocellular carcinoma patients with peritoneal carcinomatosis, though has dubious utility in pancreaticobiliary malignancies.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12957-020-01898-5","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T15:04:23Z","timestamp":1591887863000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Is cytoreductive surgery and hyperthermic intraperitoneal chemotherapy indicated in hepatobiliary malignancies?"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5691-4114","authenticated-orcid":false,"given":"Natasha","family":"Leigh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Pletcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel M.","family":"Labow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepa R.","family":"Magge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umut","family":"Sarpel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin J.","family":"Golas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,11]]},"reference":[{"key":"1898_CR1","unstructured":"National Incidence Trends, 2009-2013 [Available from: https:\/\/seer.cancer.gov\/report_to_nation\/infographics\/incidence1.html."},{"key":"1898_CR2","unstructured":"NCCN Guidelines [Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx."},{"issue":"8","key":"1898_CR3","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/bjc.2014.419","volume":"111","author":"R Mirnezami","year":"2014","unstructured":"Mirnezami R, Mehta AM, Chandrakumaran K, Cecil T, Moran BJ, Carr N, et al. Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone. Br J Cancer. 2014;111(8):1500\u20138.","journal-title":"Br J Cancer."},{"issue":"9","key":"1898_CR4","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1245\/s10434-008-9966-2","volume":"15","author":"VJ Verwaal","year":"2008","unstructured":"Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):2426\u201332.","journal-title":"Ann Surg Oncol."},{"issue":"4","key":"1898_CR5","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/jso.21054","volume":"98","author":"B Moran","year":"2008","unstructured":"Moran B, Baratti D, Yan TD, Kusamura S, Deraco M. Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei). J Surg Oncol. 2008;98(4):277\u201382.","journal-title":"J Surg Oncol."},{"issue":"5","key":"1898_CR6","doi-asserted-by":"publisher","first-page":"915","DOI":"10.21037\/jgo.2017.08.01","volume":"8","author":"A Garc\u00eda-Fadrique","year":"2017","unstructured":"Garc\u00eda-Fadrique A, Mehta A, Mohamed F, Dayal S, Cecil T, Moran BJ. Clinical presentation, diagnosis, classification and management of peritoneal mesothelioma: a review. J Gastrointest Oncol. 2017;8(5):915\u201324.","journal-title":"J Gastrointest Oncol."},{"issue":"1","key":"1898_CR7","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.5301\/tj.5000197","volume":"101","author":"SB Bhagwandin","year":"2015","unstructured":"Bhagwandin SB, Salti GI. Hepatocellular carcinoma with peritoneal metastasis treated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. Tumori. 2015;101(1):e1\u20133.","journal-title":"Tumori."},{"issue":"6","key":"1898_CR8","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/j.1445-2197.2008.04544.x","volume":"78","author":"EC Lai","year":"2008","unstructured":"Lai EC, Tang CN, Ha JP, Tsui DK, Li MK. Cytoreductive surgery in multidisciplinary treatment of advanced hepatocellular carcinoma. ANZ J Surg. 2008;78(6):504\u20137.","journal-title":"ANZ J Surg."},{"issue":"3","key":"1898_CR9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/0960-7404(94)90045-0","volume":"3","author":"WY Lau","year":"1994","unstructured":"Lau WY, Leung TW, Leung KL, Ho S, Leung N, Chan M, et al. Cytoreductive surgery for hepatocellular carcinoma. Surg Oncol. 1994;3(3):161\u20136.","journal-title":"Surg Oncol."},{"issue":"7","key":"1898_CR10","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1002\/jso.23739","volume":"110","author":"P Tabrizian","year":"2014","unstructured":"Tabrizian P, Franssen B, Jibara G, Sweeney R, Sarpel U, Schwartz M, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with peritoneal hepatocellular carcinoma. J Surg Oncol. 2014;110(7):786\u201390.","journal-title":"J Surg Oncol."},{"issue":"11","key":"1898_CR11","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1016\/j.ejso.2018.05.021","volume":"44","author":"S Mehta","year":"2018","unstructured":"Mehta S, Schwarz L, Spiliotis J, Hsieh MC, Akaishi EH, Goere D, et al. Is there an oncological interest in the combination of CRS\/HIPEC for peritoneal carcinomatosis of HCC? Results of a multicenter international study. Eur J Surg Oncol. 2018;44(11):1786\u201392.","journal-title":"Eur J Surg Oncol."},{"issue":"7","key":"1898_CR12","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1177\/000313481408000728","volume":"80","author":"RW Randle","year":"2014","unstructured":"Randle RW, Levine EA, Clark CJ, Stewart JH, Shen P, Votanopoulos KI. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for gallbladder cancer: a retrospective review. Am Surg. 2014;80(7):710\u20133.","journal-title":"Am Surg."},{"issue":"2","key":"1898_CR13","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/jso.23062","volume":"106","author":"N Golse","year":"2012","unstructured":"Golse N, Bakrin N, Passot G, Mohamed F, Vaudoyer D, Gilly FN, et al. Iterative procedures combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal recurrence: postoperative and long-term results. J Surg Oncol. 2012;106(2):197\u2013203.","journal-title":"J Surg Oncol."},{"key":"1898_CR14","doi-asserted-by":"crossref","unstructured":"Brandl A, Zielinski CB, Raue W, Pratschke J, Rau B. Peritoneal metastases of rare carcinomas treated with cytoreductive surgery and HIPEC - a single center case series. Ann Med Surg (Lond). 2017;22:7-11.","DOI":"10.1016\/j.amsu.2017.08.009"},{"issue":"5","key":"1898_CR15","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1007\/s11605-014-2477-5","volume":"18","author":"P Tabrizian","year":"2014","unstructured":"Tabrizian P, Shrager B, Jibara G, Yang MJ, Romanoff A, Hiotis S, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution. J Gastrointest Surg. 2014;18(5):1024\u201331.","journal-title":"J Gastrointest Surg."},{"key":"1898_CR16","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359\u201374.","journal-title":"Cancer Treat Res."},{"issue":"2","key":"1898_CR17","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","volume":"250","author":"PA Clavien","year":"2009","unstructured":"Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250(2):187\u201396.","journal-title":"Ann Surg."},{"issue":"6","key":"1898_CR18","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/oxfordjournals.annonc.a010676","volume":"7","author":"B Glimelius","year":"1996","unstructured":"Glimelius B, Hoffman K, Sj\u00f6d\u00e9n PO, Jacobsson G, Sellstr\u00f6m H, Enander LK, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 1996;7(6):593\u2013600.","journal-title":"Ann Oncol."},{"issue":"2","key":"1898_CR19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/01.coc.0000203742.22828.bb","volume":"29","author":"GW Lee","year":"2006","unstructured":"Lee GW, Kang JH, Kim HG, Lee JS, Jang JS. Combination chemotherapy with gemcitabine and cisplatin as first-line treatment for immunohistochemically proven cholangiocarcinoma. Am J Clin Oncol. 2006;29(2):127\u201331.","journal-title":"Am J Clin Oncol."},{"issue":"3","key":"1898_CR20","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1023\/A:1016209901417","volume":"20","author":"R Kuhn","year":"2002","unstructured":"Kuhn R, Hribaschek A, Eichelmann K, Rudolph S, Fahlke J, Ridwelski K. Outpatient therapy with gemcitabine and docetaxel for gallbladder, biliary, and cholangio-carcinomas. Invest New Drugs. 2002;20(3):351\u20136.","journal-title":"Invest New Drugs."},{"issue":"3","key":"1898_CR21","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jamcollsurg.2008.02.031","volume":"207","author":"NG Coburn","year":"2008","unstructured":"Coburn NG, Cleary SP, Tan JC, Law CH. Surgery for gallbladder cancer: a population-based analysis. J Am Coll Surg. 2008;207(3):371\u201382.","journal-title":"J Am Coll Surg."},{"key":"1898_CR22","volume-title":"Groman A","author":"RV Iyer","year":"2016","unstructured":"Iyer RV, Pokuri VK. Groman A. Malhotra U, Iancu DM, et al. A multicenter phase II study of gemcitabine, capecitabine, and bevacizumab for locally advanced or metastatic biliary tract cancer. Am J Clin Oncol: Ma WW; 2016."},{"issue":"14","key":"1898_CR23","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273\u201381.","journal-title":"N Engl J Med."},{"issue":"12","key":"1898_CR24","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/j.1477-2574.2012.00544.x","volume":"14","author":"MJ Kang","year":"2012","unstructured":"Kang MJ, Song Y, Jang JY, Han IW, Kim SW. Role of radical surgery in patients with stage IV gallbladder cancer. HPB (Oxford). 2012;14(12):805\u201311.","journal-title":"HPB (Oxford)."},{"issue":"8","key":"1898_CR25","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1093\/jjco\/hyr072","volume":"41","author":"H Meng","year":"2011","unstructured":"Meng H, Wang X, Fong Y, Wang ZH, Wang Y, Zhang ZT. Outcomes of radical surgery for gallbladder cancer patients with lymphatic metastases. Jpn J Clin Oncol. 2011;41(8):992\u20138.","journal-title":"Jpn J Clin Oncol."},{"issue":"1","key":"1898_CR26","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.canlet.2005.05.050","volume":"237","author":"T Oshikiri","year":"2006","unstructured":"Oshikiri T, Morita T, Fujita M, Miyasaka Y, Senmaru N, Yamada H, et al. Resection of lung metastasis from gallbladder carcinoma: immunohistochemistry of RCAS1 and CD8+T cells in primary and metastatic tumors. Cancer Lett. 2006;237(1):115\u201322.","journal-title":"Cancer Lett."},{"issue":"4","key":"1898_CR27","first-page":"305","volume":"66","author":"K Oyama","year":"2013","unstructured":"Oyama K, Kanzaki M, Isaka T, Kikkawa T, Komine H, Wachi N, et al. Surgery for metastatic lung tumor from malignant tumor of liver, biliary duct and pancreas. Kyobu Geka. 2013;66(4):305\u201310.","journal-title":"Kyobu Geka."},{"issue":"1","key":"1898_CR28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4103\/0019-509X.219581","volume":"54","author":"I Park","year":"2017","unstructured":"Park I, Kim YS, Sym SJ, Ahn HK, Kim KK, Park YH, et al. Metastasectomy for recurrent or metastatic biliary tract cancers: a single center experience. Indian J Cancer. 2017;54(1):57\u201362.","journal-title":"Indian J Cancer."},{"issue":"19","key":"1898_CR29","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouch\u00e9 O, Guimbaud R, B\u00e9couarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817\u201325.","journal-title":"N Engl J Med."},{"issue":"18","key":"1898_CR30","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691\u2013703.","journal-title":"N Engl J Med."},{"key":"1898_CR31","doi-asserted-by":"publisher","first-page":"939350","DOI":"10.1155\/2012\/939350","volume":"2012","author":"F Klein","year":"2012","unstructured":"Klein F, Puhl G, Guckelberger O, Pelzer U, Pullankavumkal JR, Guel S, et al. The impact of simultaneous liver resection for occult liver metastases of pancreatic adenocarcinoma. Gastroenterol Res Pract. 2012;2012:939350.","journal-title":"Gastroenterol Res Pract."},{"issue":"5","key":"1898_CR32","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s11605-009-0801-2","volume":"13","author":"M Nikfarjam","year":"2009","unstructured":"Nikfarjam M, Sehmbey M, Kimchi ET, Gusani NJ, Shereef S, Avella DM, et al. Additional organ resection combined with pancreaticoduodenectomy does not increase postoperative morbidity and mortality. J Gastrointest Surg. 2009;13(5):915\u201321.","journal-title":"J Gastrointest Surg."},{"issue":"5","key":"1898_CR33","first-page":"434","volume":"11","author":"A Singh","year":"2010","unstructured":"Singh A, Singh T, Chaudhary A. Synchronous resection of solitary liver metastases with pancreaticoduodenectomy. JOP. 2010;11(5):434\u20138.","journal-title":"JOP."},{"key":"1898_CR34","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ijsu.2017.10.066","volume":"48","author":"X Yu","year":"2017","unstructured":"Yu X, Gu J, Fu D, Jin C. Dose surgical resection of hepatic metastases bring benefits to pancreatic ductal adenocarcinoma? A systematic review and meta-analysis. Int J Surg. 2017;48:149\u201354.","journal-title":"Int J Surg."},{"issue":"4","key":"1898_CR35","first-page":"358","volume":"27","author":"F Lu","year":"2015","unstructured":"Lu F, Poruk KE, Weiss MJ. Surgery for oligometastasis of pancreatic cancer. Chin J Cancer Res. 2015;27(4):358\u201367.","journal-title":"Chin J Cancer Res."},{"issue":"9","key":"1898_CR36","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1007\/s11605-011-1605-8","volume":"15","author":"GJ Arnaoutakis","year":"2011","unstructured":"Arnaoutakis GJ, Rangachari D, Laheru DA, Iacobuzio-Donahue CA, Hruban RH, Herman JM, et al. Pulmonary resection for isolated pancreatic adenocarcinoma metastasis: an analysis of outcomes and survival. J Gastrointest Surg. 2011;15(9):1611\u20137.","journal-title":"J Gastrointest Surg."},{"issue":"19","key":"1898_CR37","doi-asserted-by":"publisher","first-page":"4475","DOI":"10.1002\/cncr.25960","volume":"117","author":"K Uchino","year":"2011","unstructured":"Uchino K, Tateishi R, Shiina S, Kanda M, Masuzaki R, Kondo Y, et al. Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Cancer. 2011;117(19):4475\u201383.","journal-title":"Cancer."},{"issue":"1","key":"1898_CR38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25\u201334.","journal-title":"Lancet Oncol."},{"key":"1898_CR39","doi-asserted-by":"crossref","unstructured":"Ding JH, Chua TC, Al-Mohaimeed K, Morris DL. Hepatocellular carcinoma peritoneal metastases: report of three cases and collective review of the literature. Ann Acad Med Singapore. 2010;39(9):734-4.","DOI":"10.47102\/annals-acadmedsg.V39N9p734"},{"issue":"5","key":"1898_CR40","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/j.1440-1746.2009.05848.x","volume":"24","author":"CC Lin","year":"2009","unstructured":"Lin CC, Liang HP, Lee HS, Huang GT, Yang PM, Ho MC, et al. Clinical manifestations and survival of hepatocellular carcinoma patients with peritoneal metastasis. J Gastroenterol Hepatol. 2009;24(5):815\u201320.","journal-title":"J Gastroenterol Hepatol."},{"issue":"24","key":"1898_CR41","first-page":"20","volume":"1","author":"J Spiliotis","year":"2017","unstructured":"Spiliotis J, Nikolaou G, Kopanakis N, Vassiliadou D, Terra A, Efstathiou E. Hepatocellular carcinoma peritoneal metastasis: role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Gulf J Oncolog. 2017;1(24):20\u20133.","journal-title":"Gulf J Oncolog."}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-020-01898-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-020-01898-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-020-01898-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T07:54:52Z","timestamp":1696233292000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-020-01898-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,11]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1898"],"URL":"https:\/\/doi.org\/10.1186\/s12957-020-01898-5","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,11]]},"assertion":[{"value":"13 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Icahn School of Medicine at Mount Sinai IRB.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"124"}}